Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on September 21, 2020. The filing serves as a Regulation FD disclosure to announce that the Company intends to conduct meetings with third parties to present its corporate slide presentation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural disclosure regarding investor communications and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely discloses the intent to distribute a corporate presentation to third parties.
Guidance, Outlook, and Risks
The filing includes a standard legal disclaimer stating that the information furnished under Item 7.01 and the attached Exhibit 99.1 (Company Presentation) are deemed "furnished" and not "filed" under Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section and shall not be incorporated by reference into any other filings. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K.
Key Facts for Investor Verification
- The filing is a Regulation FD disclosure dated September 21, 2020.
- Cardiff Oncology, Inc. plans to present its corporate slide deck to third parties.
- The attached presentation (Exhibit 99.1) is not considered "filed" for liability purposes under Section 18 of the Exchange Act.
- No financial data or operational metrics are included in this specific report.